Výzkum

Aminoacetic acid (glycine) and prostigmine

3 women with DD a diet

• 70 grams protein,
• 70 grams of fat
• 100 grams carbohydrate
• 1500 calories/day (specifics unavailable)
• 10 grams glycine
• 45 mg prostigmine daily improves asthenia.
• Improved weight loss and energy
• If glycine binding in the central nervous system is antagonized
• Feeding in rats increased
• Glycine may therefore be an appetite suppressant
• www.ncbi.nlm.nih.gov/pmc/articles/PMC4010336/

Ruxolitinib

• A drug that targets the JAK2 gene
• Role in the development of lipoedema

Adipocyte-derived stem cells

• Ability to differentiate into different types of cells, including fat cells
• May have the potential to be used in the treatment of lipoedema.

Roflumilast

• A phosphodiesterase-4 (PDE4) inhibitor
• Reduce inflammation and improve insulin sensitivity in preclinical studies.

Adipose tissue-derived mesenchymal stem cells (AT-MSCs)

• AT-MSCs have a potential to differentiate into adipocytes and other cells types.
• AT-MSCs have been used in preclinical studies as a lipoedema treatment.

Doxorubicin

• Anthracycline antibiotic
• Reduce the size of fat cells in preclinical studies.

Rapamycin

• Reduce the size of fat cells in preclinical studies.

Gene therapy

Some studies

• Gene therapy to target specific genes involved in the development of lipoedema
• Aims to reduce the symptoms of lipoedema by altering the activity of certain genes.

Stem cell therapy

Some studies

• Stem cell therapy to repair damaged fat cells and improve the function of the lymphatic system in people with lipoedema.

MicroRNA therapy

Some studies

• MicroRNA therapy to target specific miRNA molecules that are involved in the development of lipoedema.

Anti-VEGF drugs

• Inhibit the growth of new blood vessels
• Reduce inflammation
• May be beneficial in treating lipoedema
• More research is needed to determine the effectiveness

Ruxolitinib

• A drug that targets the JAK2 gene
• Role in the development of lipoedema.

Adipocyte-derived stem cells

• Ability to differentiate into different types of cells, including fat cells
• May have the potential to be used in the treatment of lipoedema.

Roflumilast

• A phosphodiesterase-4 (PDE4) inhibitor
• Reduce inflammation and improve insulin sensitivity in preclinical studies.

Adipose tissue-derived mesenchymal stem cells (AT-MSCs)

• AT-MSCs have a potential to differentiate into adipocytes and other cells types.
• AT-MSCs have been used in preclinical studies as a lipoedema treatment.

Tesamorelin

• A synthetic analogue of human growth hormone-releasing hormone
• FDA-approved for the reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy
• Visceral adipose tissue was reduced up to 18% during active use of tesamorelin
• www.ncbi.nlm.nih.gov/pmc/articles/PMC4010336/